• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Holdings Inc. Strengthens Team with Appointment of Experienced Accounting Team

    11/11/24 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email

    Edward Deignan Appointed as VP of Finance and Accounting Kyle Degruttola Appointed as Controller

    NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Dominari Holdings Inc. (NASDAQ:DOMH) (the "Company") today announced that it has appointed Edward Deignan as Vice President of Finance and Accounting and Kyle Degruttola as Controller. Together, they bring decades of accounting and finance leadership experience from various multi-national and public sector organizations.

    Mr. Deignan is responsible for the day-to-day management of the Company's financial operations. He brings with him more than 30 years of experience in accounting, finance and banking. He has served as a chief financial officer for several companies over the past decade. He is a certified public accountant and holds a Bachelor of Science degree in accounting from Seton Hall University.

    Mr. Degruttola is responsible for directing all accounting operations. He brings with him more than 20 years of experience in accounting and finance, including serving as a collegiate professor of accounting and computer science at Wood Tobe-Coburn College and Union County College. Most recently, he served as Controller for the City of Jersey City. Prior to that, he served as the private equity accounting manager for US Retirement & Benefit Partners. He is a certified public accountant, a Series 27 financial and operations principal and holds a Bachelor of Science in accounting from Kean University.

    For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/.

    About Dominari Holdings Inc.

    Dominari Holdings Inc. (the "Company"), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. ("Dominari Financial"), with the intent of shifting the Company's primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC ("Dominari Securities"), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority ("FINRA") and an investment adviser registered with the Securities and Exchange Commission ("SEC"). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Contacts:

    Dominari Holdings Inc.
    https://www.dominariholdings.com/

    Investor Relations
    Hayden IR
    Brett Maas, Managing Partner
    Phone: (646) 536-7331
    Email: brett@haydenir.com
    www.haydenir.com

    SOURCE: Dominari Holdings



    View the original press release on accesswire.com

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ledwick Tim S

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/25/26 8:10:56 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hayes Anthony

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:32 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haug Kyle

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:14 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Rise of the American Drone Industry

    NEW YORK, June 2, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today issued the following letter to shareholders: Dear Shareholder,The rise of drones in our society has become ubiquitous. Whether it's the discussion of their use to make deliveries, their use to cover sporting events, or their constant presence when discussing conflicts in the middle east, drones are everywhere. And at Dominari, we are proud to play our part in building and supporting this growing American industry.Since our inception, Dominari has been involved in supporting this important new facet

    6/2/26 8:00:00 AM ET
    $DOMH
    $JFB
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    General Bldg Contractors - Nonresidential Bldgs
    Consumer Discretionary

    Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering

    Shares Skyrocket in Debut as AI Mania Grips Wall Street According to ReutersNEW YORK, May 15, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") congratulates Cerebras Systems (NASDAQ:CBRS), on its Initital Public Offering, which has been called a "Blockbuster Debut" as the next hot AI stock, by Investor's Business Daily. On May 14, 2026, Cerebras stock opened at $185.00 and closed $126 higher at $311.07 per share, an approximate 68% increase on its first day of trading. Dominari Securities' SPV 1 & 2 invested early in Cerebras, at $39.00 per

    5/15/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    5/27/26 5:00:42 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Dominari Holdings Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    5/12/26 9:42:51 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    3/31/26 9:20:25 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Q1 Revenue Increases by 395% Over Q1 2025

    Underwriting revenues increased over five-fold NEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended March 31, 2026, which were filed with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. The Company stated that:  "In  the first quarter of 2026,  we experienced continued revenue growth mainly from underwriting services, increased our annual recurring revenue from our management fees that we earn on deals that we bri

    5/13/26 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces Record Date for Cash Dividend

    NEW YORK, May 4, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $9 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/About Dominari Holdings Inc.The C

    5/4/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care